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Abstract Radiosynoviorthesis is used for the local treat-
ment of recurrent joint eVusions and leads to synovium
necrosis after radionuclide administration. This procedure
provides opportunity to full recovery of normal synovium
function after local corticosteroids and systemic modifying
drugs failure.
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Introduction
Radiosynoviorthesis (RS) has established position in rheu-
matology, and it is usually used in rheumatoid arthritis
(RA) and inXammatory spondyloarthropaties (SPA). The
primary indication for RS is treatment of recurrent joint
eVusions among patients who obtained general improve-
ment after systemic therapy but one or a few joints stay
resistant to this treatment. Nowadays RS is an alternative
method toward synovectomy, and it supports disease modi-
fying anti-rheumatic drugs (DMARDs) therapy [1–3].
In the presence of last clinical research results conducted
in vitro on human chondrocytes and in vivo on animals
chondrocytes which indicated harmful inXuence of RS on
articular cartilage, we have evaluated concentration of cho-
sen bone and cartilage turnover markers and acute phase
proteins in around procedure period in RA and SPA
patients [4].
Groups and methods
Seventy-one patients were included in this research; we
divided all of them into two groups. Forty-three patients
with RA (43 knee joints) aged 22–68 (on average 50,
1 year) and 19 SPA patients (19 knee joints) aged 20–70
(on average 42, 6 years) were treated with RS and then
observed during 6 months. Among 19 SPA patients, 8 were
treated due to ankylosing spondylitis (AS), 4 due to psori-
atic arthritis (PsA), and 7 due to undiVerentiated inXamma-
tory spondyloarthropaty.
On the basis of knee X-rays taken not longer than 1 month
before RS, considering those pictures, 23 knee joints patients
with RA were classiWed as I grade according to Steinbröcker
staging, 18 knee joints patients with RA as II grade, and 2
knee joints patients with RA as III anatomical grade.
Indication for RS was moderate or severe, persistent
knee joint eVusion that was recurrent in spite of local corti-
costeroid injections (minimum of 3 given in 4–6 weekly
intervals) and optimal systemic treatment of disease with
modifying drugs in a stable dose for a period not shorter
than 4 weeks before RS. Intraarticular injection with corti-
costeroid was prohibited within 4 weeks before RS.
Patients were assigned randomly to the therapeutic appro-
priate procedure, and DMARDs were sustained in stable
doses for 6-month observation period after RS. Any
DMARDs dose change or intraarticular corticosteroid
injection within 6 months after RS excluded patient from
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failure.
Each patient signed an informed consent form before
any study related procedure and further observation after
therapy. The written approval for conducting the study and
obtaining an informed consent form was given by the Inde-
pendent Ethics Committee of the Medical University in
Lublin, Poland.
Technique of radiosynoviorthesis
The procedure was performed as follows. The knee joint
was punctured with 20 G needle and inXammatory Xuid
was evacuated, then 1 ml of sterile suspension of 90Yttrium
isotype (90Y, CIS Bio International Company) with activity
of 185 MBq (5 mCi) and 1 ml of 40 mg triamcynolon (Pol-
cortolon 40 Jelfa Company) were injected. The procedure
ended Xushing channel of needle with 4 ml of 0.9% saline.
RS was performed in aseptic conditions. After injection of
all substances and dressing the wound, three passive move-
ments for homogenic isotype distribution in joint space
were performed; afterward joint was stabilized for 48 h to
avoid radionuclide molecules migration to peripheral
lymph nodules [3].
Three-phase bone scintigraphy of knee joints
The three-phase bone scintigraphy was performed before
and 6 months after RS behind assistance of gamma camera
Varicam (Elscint, Haifa, Izrael).
The three-phase bone scintigraphy was performed after
intravenous injection of 740 MBq metylbiphosphonian
MDP-99mTc above knee joint in antero-posterior and pos-
tero-anterior projection in all phases of examination. The
third phase of knee joints scintigraphy was estimated in
semi-quantitive ROI (Region of Interest) method. We cal-
culated J/B (Joint/Bone) ratio by dividing average number
of pixels in treated region knee joint by average number of
pixels in a distal part of the femoral bone body on the
treated joint side.
We evaluated cured joints after 24 weeks of RS in the
scope of tissue blood supply and metabolism and compared
it with the state before therapy according to the procedure
described above.
EVusion evaluation of knee joint
The eYcacy of procedure was evaluated on the basis of
physical examination taking into account the presence of
eVusion before procedure and then in the Wrst and sixth
month after RS according to the placed scheme:
1) joint free of eVusion—very good result
2) mild eVusion (trace of patella balloting)—good result
3) moderate eVusion (marked patella balloting)—lack of
improvement
4) severe eVusion (in up-right knee position and muscle
relaxation articular capsule tense)—lack of improve-
ment or deterioration
Biochemical and serological designations
Following were taken from each of patients: erythrocyte
sedimentation rate (ESR, normal range: 0–15 mm/h), C-
reactive protein level (CRP, normal range 0–5 mg/l) immu-
noturbidymetric method and osteoprotegerin level (OPG,
normal range: 1.7–5.4 pmol/l), hialuronic acid (HA, normal
range: 0–75 ng/ml) and serum amyloid A (SSA, normal
range: 10–270 ng/ml) ELISA method in serum, directly
before RS (1st period), then 4 (2nd period) and 24 weeks
(3rd period) after procedure.
Statistical analysis
Statistical analysis of results was conducted with usage of
computer program STATISTICA 6.0 StatSoft company.
We calculated average arithmetic (M) for quantitative fea-
tures and standard deviation (SD).
Shapiro–Wilk W test was used for analysis of schedule
of evaluated features. Mann–Whitney U test was used to
estimate the diVerences between researched groups. We
estimated diVerences between analyzed features using
Spearman’s correlation test, Anova Friedman test, Ken-
dall’s ratio of correspondence, Wilcoxon’s couples corre-
spondence, and chi square test. We accepted for statistically
important diVerences for P < 0.05.
Results of research
Patients with moderate or severe knee eVusion were quali-
Wed for RS. Physical examination which evaluated presence
of knee eVusion in the joint treated was of primary impor-
tance of treatment eYcacy.
We observed very good results in 25 patients with RA
(58.1%)—lack of eVusion, in 10 patients good result—mild
eVusion (23.3%), lack of improvement in 8 patients
(18.6%). Very good and good results all together satisWed
35 patients (81.4%).123
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(63.2%)—lack of eVusion, in 5 patients good result—mild
eVusion (26.3%), lack of improvement in 2 patients
(10.5%). Very good and good results all together satisWed
17 patients (89.5%).
We did not observe signs of deterioration and no side
eVects connected with the procedure.
Changes in serum HA, OPG, and SAA levels after RS
are presented in Figs. 1, 2, 3, 4, 5, and 6.
Discussion
The primary inXammatory process primarily involving
synovial membrane is an essential phenomenon in systemic
arthritis; it leads to secondary changes in composition and
physico-chemical speciWcity of synovial Xuid. Breakout of
synovio-vessel barrier by activated macrophages and lym-
phocytes, inWltration, and interaction of these cells with
synoviocytes, dendritic, and endothelial cells results in
Wbroblastes expansion, neovascularization, increasing
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metaloproteinases [5, 6]. The newly synthesised pathologi-
cal tissue named pannus is responsible for destruction of all
joint structures. The purpose of RS is obliteration of hyper-
trophic and inWltrated synovial membrane and joint protec-
tion before damage [7].
In our research, we took into consideration, beyond clin-
ical examination, results of laboratory tests, scintigraphic
investigations, and generally used in daily practice scales
and questionnaires for general disease activity evaluation.
According to collected data, we observed that mentioned
parameters undergo dynamic changes inXuenced by local
therapy used. Results interchangeably indicate not only
local eYciency of RS but also favorable inXuence of proce-
dure on systemic inXammatory process as well.
The presence of knee eVusion during physical examina-
tion in the sixth month of observation was the most impor-
tant feature of treatment eYciency.
Treatment of knee eVusion with the use of RS was safe
and eYcient—we did not observe any procedure-related
adverse events.
We found only a few articles in professional literature
available evaluating inXuence of RS on unspeciWc, sys-
temic inXammatory process, and the reports are contradic-
tory [8, 9]. Spooren and co-workers did not Wnd any
inXuence of 90Y RS on red blood cells count, ESR, and
rheumatoid factor level in osteoarthritis and in patients with
RA [9]. Schutte and Rau came to the diVerent conclusions.
In patient’s group with improvement after RS, they
observed simultaneously increased level of hemoglobin and
decreased level of ESR [8].
We found in our research statistically essential decrease
in CRP concentration and ESR in the Wrst and sixth month
after RS in patients with RA. We observed decrease in
DAS (disease activity score), RADAI (rheumatoid arthritis
disease activity index), HAQ (health assessment question-
naire), VAS (visual analog scale)—physician evaluation of
disease activity, VAS—patient’s pain and disease activity
assessment scales, and swollen and tender joint counts in
the Wrst and sixth month after RS.
The obtained results indicate the favorable inXuence of
local RS therapy on unspeciWc, systemic inXammatory pro-
cess and general disease activity.
In RA and SPA patients with good and very good treat-
ment results, local and general improvement was obtained
within the Wrst month and had a permanent character, lasted
for the whole 6-month observation period.
It is known that RS has inXuence on diVerent synovial
cells metabolism, refractory to this phenomenon, secretion
of some markers activity have been changing, among others
HA, which is synthesized by Wbroblastes (synoviocytes B
in synovium) penetrates blood via lymph vessels and it is
eliminated by liver. Research conducted on animals and
humans in vivo conWrmed its protective role for articular
cartilage provides chondrocytes viability and decreases
proliferation of synovial cells. HA has anti-inXammatory
properties and binds free ties. It plays important role in cor-
rect joints’ motion, reduces friction, and creates kind of
“lubrication” covering articular surfaces [10–13].
The highest concentration of HA is observed in patients
with RA, a little bit lower in AS and PsA patients; in osteo-
arthritis patients, HA level is comparable to population of
healthy persons [14, 15]. It is known that HA concentration
correlates with objective markers of inXammatory process
in RA and AS such as CRP level and ESR value and addi-
tionally in AS with a scope of spine motion. The higher
level of HA is presented in AS patients with peripheral
joints involvement [15]. High level of HA in patients with
systemic inXammatory arthritis results from overproduction
of polysaccharide within synovial membrane, while it is not
related to poor liver elimination, it reXects the degree of
cartilage degradation [16, 17]. Some authors include HA to
one of the most important markers of RA and juvenile
arthritis activity [18].
We found in our research highly signiWcant statistically
decrease in serum HA level in patients with RA in the Wrst
and sixth month after RS which suggests important inXu-
ence on this treatment on reducing of local inXammatory
process through interaction on synovial membrane of the
treated knee joint. However, increase in the HA level was
observed in SPA patients in the sixth month after RS.
Another group of proteins used in monitoring of
inXammatory activity and taking part in maintaining bone
tissue homeostasis is a system of receptors and ligands of
cancer necrosis factors. OPG is a protein belonging to a
family of receptors of cancer necrosis factors, universally
it is found in a body, produced within the heart, lungs,
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OPG is produced in large quantities by synovial mem-
brane Wbroblasts. RANKL (receptor activator NF-B
ligand) belongs to a family of proteins of cancer necrosis
factors, produced by mature osteoblats and their precur-
sors, macrophages, and activated lymphocytes T [19, 20].
RANKL regulates diVerentiation of osteoclasts and den-
dritic cells, acts through a receptor RANK (receptor acti-
vator NF-B) situated on a surface of target cells [19].
OPG has ability of binding RANKL, it constitutes its sol-
uble receptor, binding block of RANK from RANKL
stops osteoclasts maturation just at its initial stages.
DiVerentiation, maturation, and activity of osteoclasts,
and so intensity of the bone resorption depend on relative
balance between the concentration of RANKL and OPG.
The RANKL advantage over OPG is increasing patholog-
ically the process of the bone resorption, a phenomenon
responsible for the generalized and periarticular osteopo-
rosis development, and for bone erosions in systemic
arthritides [19–21].
In conducted examinations, we stated an essential statis-
tical increase in the OPG concentration after the Wrst month
from RS in SPA patients and after the sixth month from RS
in patients with RA, which suggests the protective inXuence
of this procedure on joint cartilage and on sub-cartilage
bone layer.
In the group of SPA patients after RS, we observed
essential statistically decrease in the SAA concentration
after the Wrst and sixth month from performing the proce-
dure.
SAA is produced in the liver, after being released to
blood, it is bound with HDL (high density lipoproteins)
fulWlls anti-inXammatory functions; its concentration in
serum repeatedly grows during the inXammatory reaction.
It is a fundamental marker of acute phase, SAA synthesis
is mainly stimulated by Il 1 and Il 6. RA and SPA are
included in typical inXammatory chronic arthritides,
where SAA high concentrations in the patients’ serum are
stated. HDL molecules are protecting SAA from the pro-
teolysis. Complexes HDL-SAA are responsible for che-
motaxis of monocytes, lymphocytes, mast cells and are
activating tissue proteinases: collagenase and stromyely-
sin. Complexes HDL-SAA are the source of cholesterol
for the regeneration of cells damaged by the inXammatory
process and simultaneously can act as the carrier of lipids
by binding the excess of cholesterol in serum, which is
being freed from destroyed tissues. The SAA excess in the
chronic inXammable process in relation to the organic
protein deposition leads to the reactive amyloidosis. The
frequency of amyloidosis appearance in RA Xuctuates
from 11 to 30%, most often accompanies AS on the SPA
course (6%).
In own examinations statistically essential negative cor-
relation was stated between the anatomical stage and the
eVectiveness of therapy. This observation is matching data
in literature [22, 23].
No essential statistical relations were found between the
age of patients, sex, duration of illness, number of RS per-
formed earlier, number of modifying drugs used earlier,
and the subjective and objective evaluation of the joint
treated before the procedure with the therapy eVectiveness.
Initial, general activity of arthritis evaluated on the basis
of the concentration of acute phase proteins (CRP, Wbrino-
gen, albumin), OPG, HA, SAA in serum, number of painful
and swollen joints, questionnaires (HAQ), indices
(RADAI), scores (DAS), and local evaluation based on
articular liquid examination (pleocytosis with smear) did
not correlate with the therapy eVectiveness.
The response to treatment in groups of RA and SPA
patients after RS was also determined on the basis of
changes in the third metabolic phase of the three-phase
scintigraphy of knee joints. Statistically signiWcant positive
correlation between the eVectiveness of therapy evaluated
on the basis of the physical examination was stated toward
the eVusion and the initial value of the J/B rate established
before the treatment. Achieved results are matching data
from the literature [23–27]. The eVectiveness of therapy
negatively correlated with the J/B value after 6 months
observation. So the initial value of the J/B rate is prognosing
the eVectiveness of therapy. The J/B rate is not correlating
with the subjective evaluation made before and after 6
monthly period of observation.
Conclusions
1. Radiosynoviorthesis with 90Yttrium is safe procedure
in persistent knee joints eVusions in relation to rheuma-
toid arthritis and spondyloarthropaty patients.
2. Radiosynoviorthesis with 90Yttrium of knee joints in
spite of being local treatment reduces unspeciWc
inXammatory process and systemic disease activity in
subjects with rheumatoid arthritis and inXammatory
spondyloarthropaties.
3. Radiological stage has negative correlation with treat-
ment eYcacy.
4. Favorable changes of serum bone and cartilage turn-
over markers as the eVect of therapy indicate protective
impact of radiosynoviorthesis on those articular struc-
tures.
5. Therapeutic response after radiosynoviorthesis based
on physical examination, biochemical markers of acute
phase, speciWc scales, and questionnaires is gained
quickly and lasts for a minimum of 6 months.123
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